NCT05304949View on ClinicalTrials.gov

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

CompletedOBSERVATIONAL
Enrollment

69

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

January 11, 2025

Study Completion Date

January 11, 2025

Conditions
Retinopathy of Prematurity
Interventions
OTHER

Lucentis

There was no treatment allocation. Patients administered Lucentis by prescription were enrolled.

Trial Locations (6)

13620

Novartis Investigative Site, Bundang Gu

42602

Novartis Investigative Site, Daegu

03722

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

06273

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY